Anatara Lifesciences (ANR) Stock Price, News & Analysis

Company Overview

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3,950 shs
• Average Volume: N/A
• Market Capitalization: A$11.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Anatara Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anatara Lifesciences investors own include Woodside Petroleum (WPL), Temple & Webster Group (TPW), Brompton Oil Split (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:ANR
• CIK: N/A
• Web: www.anataralifesciences.com
• Phone: 61 7 3394 8202
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$1.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -110.25%
• Return on Assets: -59.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.49
• Quick Ratio: 4.69

Sales & Book Value

• Annual Sales: A$1.25 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.33
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 192,890,000
• Free Float: N/A
• Market Cap: A$11.74 million
• Optionable: Not Optionable
• Beta: 0.72